Rockville, Maryland, March 29, 2021

  • TCR2 acquires lease for 85,000 square foot state-of-the-art facility being built in Rockville, Maryland
  • Accelerates TCR2’s commercial-scale manufacturing timelines with production anticipated in 2023
  • Aaron Vernon hired as Vice President of Technical Operation

In addition to the recent announcement of TCR2’s acquisition of the 85,000 sq foot facility through the long-term full building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE), TCR2 also acquired another key asset that almost makes these transactions seem like a package deal – Aaron Vernon.   Recently hired as TCR2’s VP of Technical Operations, Vernon was previously the VP of Global Technical Operations, Engineering & Supply Chain at Autolus Therapeutics, who had originally began construction of the state of the art facility in 2019 to support production for their pipeline of cell therapy products currently in clinical trials.

In a series of strategic transactions, TCR2 has acquired a cutting edge cell therapy manufacturing facility that is ready for Current Good Manufacturing Practice (cGMP) build-out, along with a veteran engineering and operations leader, Aaron Vernon, who was intimately responsible for the building since its initial design and construction and who will now continue to see the building reach it’s ultimate purpose – to produce life saving therapies for cancer patients, now anticipated in 2023.

“The hiring of Aaron Vernon to head technical operations for the Company comes at the right time as we expand our manufacturing capabilities in anticipation of commercial production. His prior leadership roles in building out commercial operations as well as his specific expertise in global supply chain management will offer vital insights to TCR2 as we continue to execute upon our clinical strategy for gavo-cel,” added Dr. Menzel.

Aaron Vernon joins TCR2 as Vice President of Technical Operations. Most recently, he held senior positions including Vice President of Global Technical Operations and Vice President of Engineering & Supply Chain at Autolus Therapeutics, a clinical stage autologous CAR-T cell therapy company, where he held numerous responsibilities including manufacturing capacity expansion and overseeing internal and external manufacturing of plasmid, vector and cell therapy products. Previously, Aaron was Vice President of Global Supply Chain and Manufacturing at Sucampo Pharmaceuticals. Earlier in his career, served in various engineering and manufacturing operations roles at AstraZeneca, MedImmune and Johnson & Johnson.

Read the full article at: